Proqr Therapeutics

Proqr Therapeutics company information, Employees & Contact Information

Changing lives is what drives us at ProQR Therapeutics. We are advancing our proprietary Axiomer™ RNA-editing platform technology. Our highly energetic team strives to combine innovative technologies and entrepreneurism to make a meaningful impact on the lives of individuals and the people around them. If you are up to this challenge and like to be part of our team, check out our website for vacancies: http://www.proqr.com/careers/

Company Details

Employees
194
Founded
-
Address
Zernikedreef 9, Leiden,zuid-Holland 2333ck,netherlands
Phone
0031-0854894932
Email
in****@****oqr.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Website
proqr.com
HQ
Leiden, Zuid-Holland
Looking for a particular Proqr Therapeutics employee's phone or email?

Proqr Therapeutics Questions

News

ProQR to Participate in Upcoming Investor Conferences in October 2025 - Yahoo Finance

ProQR to Participate in Upcoming Investor Conferences in October 2025 Yahoo Finance

ProQR Therapeutics to Participate in Upcoming Investor Conferences with Focus on RNA Editing Technology - Quiver Quantitative

ProQR Therapeutics to Participate in Upcoming Investor Conferences with Focus on RNA Editing Technology Quiver Quantitative

CTA Authorization: AX-0810 Phase 1 Trial Authorized for Dosing — ProQR to Host Virtual Investor Event Nov 3, 2025 - Stock Titan

CTA Authorization: AX-0810 Phase 1 Trial Authorized for Dosing — ProQR to Host Virtual Investor Event Nov 3, 2025 Stock Titan

ProQR Therapeutics Advances Axiomer RNA Editing Pipeline with Key Milestones Set for 2025 - Nasdaq

ProQR Therapeutics Advances Axiomer RNA Editing Pipeline with Key Milestones Set for 2025 Nasdaq

ProQR Advances First RNA Editing Therapy to Clinical Trials for Liver Disease | PRQR Stock News - Stock Titan

ProQR Advances First RNA Editing Therapy to Clinical Trials for Liver Disease | PRQR Stock News Stock Titan

ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP - GlobeNewswire

ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP GlobeNewswire

ProQR Therapeutics Updates on AX-0810 Clinical Trial Submission and Financial Results for Q2 2025 - Quiver Quantitative

ProQR Therapeutics Updates on AX-0810 Clinical Trial Submission and Financial Results for Q2 2025 Quiver Quantitative

Lilly and ProQR to Expand RNA Editing Collaboration - PR Newswire

Lilly and ProQR to Expand RNA Editing Collaboration PR Newswire

ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement - GlobeNewswire

ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement GlobeNewswire

ProQR Announces Axiomer® RNA Editing Licensing and Research Collaboration with Lilly - GlobeNewswire

ProQR Announces Axiomer® RNA Editing Licensing and Research Collaboration with Lilly GlobeNewswire

ProQR Announces Webcast of Presentation at the Upcoming Stifel 2022 Healthcare Conference - GlobeNewswire

ProQR Announces Webcast of Presentation at the Upcoming Stifel 2022 Healthcare Conference GlobeNewswire

ProQR Therapeutics: Not A Needle Mover Just Yet - Seeking Alpha

ProQR Therapeutics: Not A Needle Mover Just Yet Seeking Alpha

ProQR Therapeutics Second Quarter 2025 Earnings: Misses Expectations - Yahoo Finance

ProQR Therapeutics Second Quarter 2025 Earnings: Misses Expectations Yahoo Finance

ProQR Therapeutics and Yarrow Biotechnology, an RTW - GlobeNewswire

ProQR Therapeutics and Yarrow Biotechnology, an RTW GlobeNewswire

ProQR, Théa ink new $8.6M pact for eye assets after old one collapsed - Fierce Biotech

ProQR, Théa ink new $8.6M pact for eye assets after old one collapsed Fierce Biotech

Lilly pays $75M to widen RNA editing deal with ProQR - BioPharma Dive

Lilly pays $75M to widen RNA editing deal with ProQR BioPharma Dive

StockWatch: Wave’s RNA Editing Milestone Lifts Korro, ProQR - Genetic Engineering and Biotechnology News

StockWatch: Wave’s RNA Editing Milestone Lifts Korro, ProQR Genetic Engineering and Biotechnology News

Lilly doubles down on ProQR's RNA tech in $75M deal expansion, spurring biotech's much-needed share rally - Fierce Biotech

Lilly doubles down on ProQR's RNA tech in $75M deal expansion, spurring biotech's much-needed share rally Fierce Biotech

ProQR shares plummet as eye disease treatment flops phase 2/3 pediatric trial - Fierce Biotech

ProQR shares plummet as eye disease treatment flops phase 2/3 pediatric trial Fierce Biotech

ProQR slashes 30% of workforce following phase 2/3 blunder - Fierce Biotech

ProQR slashes 30% of workforce following phase 2/3 blunder Fierce Biotech

ProQR strengthens leadership team - The Pharma Letter

ProQR strengthens leadership team The Pharma Letter

ProQR Announces Positive Findings From an Interim Analysis - GlobeNewswire

ProQR Announces Positive Findings From an Interim Analysis GlobeNewswire

Native Structural and Functional Proteoform Characterization of the Prolyl-Alanyl-Specific Endoprotease EndoPro from Aspergillus niger - ACS Publications

Native Structural and Functional Proteoform Characterization of the Prolyl-Alanyl-Specific Endoprotease EndoPro from Aspergillus niger ACS Publications

How ProQR aims to use RNA therapy to target genetic forms of blindness - drugdiscoverytrends.com

How ProQR aims to use RNA therapy to target genetic forms of blindness drugdiscoverytrends.com

Intravitreal antisense oligonucleotide sepofarsen in Leber congenital amaurosis type 10: a phase 1b/2 trial - Nature

Intravitreal antisense oligonucleotide sepofarsen in Leber congenital amaurosis type 10: a phase 1b/2 trial Nature

ProQR Receives Orphan Drug Designation from FDA for Drug - GlobeNewswire

ProQR Receives Orphan Drug Designation from FDA for Drug GlobeNewswire

ProQR licenses Ionis’ RNA drug for inherited blindness - Fierce Biotech

ProQR licenses Ionis’ RNA drug for inherited blindness Fierce Biotech

Landscape of genetic therapies for USH2A-related retinitis pigmentosa - Ophthalmology Times Europe

Landscape of genetic therapies for USH2A-related retinitis pigmentosa Ophthalmology Times Europe

ProQR Announces Clinical Data Presentations and Investor & Analyst Event at NACFC - GlobeNewswire

ProQR Announces Clinical Data Presentations and Investor & Analyst Event at NACFC GlobeNewswire

ProQR surges on CF data on busy day for the field - Fierce Biotech

ProQR surges on CF data on busy day for the field Fierce Biotech

ProQR Therapeutics (PRQR) Stock Price, News & Analysis - MarketBeat

ProQR Therapeutics (PRQR) Stock Price, News & Analysis MarketBeat

Top Proqr Therapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant